Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Prostatic Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Sarcoma, Kaposi 3Neoplasms 3Breast Neoplasms 3Acquired Immunodeficiency Syndrome 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasm Metastasis 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2HIV Infections 2Glioma 2Glioblastoma 2Endometrial Neoplasms 2Brain Neoplasms 2Wilms Tumor 1Weight Loss 1Vulvar Neoplasms 1Vaginal Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Thyroid Cancer, Papillary 1Thrombocytopenia 1Splenomegaly 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sezary Syndrome 1

Interventions

Epoetin Alfa 55Darbepoetin alfa 39epoetin beta 14ferric carboxymaltose 11Lenalidomide 5Cyclophosphamide 5luspatercept 4fludarabine phosphate 4fludarabine 4Erythropoietin 4Cyclosporine 4Cisplatin 4Busulfan 4Blood Transfusion 4Biopsy 4ACE-011 4peginesatide 3iron isomaltoside 1000 3hematide 3ferrous sulfate 3ferric gluconate 3Radiotherapy 3Iron-Dextran Complex 3Filgrastim 3Ferric Oxide, Saccharated 3Erythrocyte Transfusion 3Antilymphocyte Serum 3thymoglobulin 2telapristone acetate 2ruxolitinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anemia × Ritonavir × Clear all
NCT02948283 2021-02-12

Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia

City of Hope Medical Center

Phase 1 Completed
3 enrolled
Classical hematologyLymphoidOther hematologic neoplasmPlasma cell

Lymphadenopathy, Anemia, Fatigue, Fever, Lymphocytosis, Multiple Myeloma, Splenomegaly, Thrombocytopenia, Weight Loss, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡